Fluvoxamine augmentation in risperidone‐resistant schizophrenia: an open trial

Takashi, Hitoshi; Sugita, Takio; Higuchi, Hisashi; Shimizu, Tetsuo

doi:10.1002/hup.367

Cited by 13 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Silver et al 36,37 reported that fluvoxamine add-on therapy improved negative symptoms of patients with chronic schizophrenia who received typical or atypical antipsychotics. Takahashi et al 71 reported that fluvoxamine appeared to be ineffective on the PANSS scores in augmenting the risperidone treatment response in chronic schizophrenic patients. 70 In addition, fluvoxamine addon therapy did not improve the PANSS scores.…”

Section: Discussionmentioning

confidence: 99%

“…However, a meta-analysis demonstrated no global support for an improvement in negative symptoms with SSRI augmentation therapy in schizophrenia. 36,37,71 However, 1 patient who had previously received olanzapine medication deteriorated with regard to positive symptoms in the follow-up phase, but not in the add-on phase. Takahashi et al 71 reported that fluvoxamine appeared to be ineffective on the PANSS scores in augmenting the risperidone treatment response in chronic schizophrenic patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia

Niitsu

Fujisaki²,

Shiina³

et al. 2012

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Cognitive impairments in schizophrenia are associated with suboptimal psychosocial performance. Several lines of evidence have suggested that endoplasmic reticulum protein sigma-1 receptors were involved in cognitive impairments in patients with schizophrenia and that the sigma-1 receptor agonist fluvoxamine was effective in treating cognitive impairments in animal models of schizophrenia and in some patients with schizophrenia. A randomized, double-blind, placebo-controlled, parallel trial of fluvoxamine adjunctive therapy in patients with schizophrenia was performed. A total of 48 patients with chronic schizophrenia were enrolled. Subjects were randomly assigned to an 8-week administration of add-on fluvoxamine (n = 24, titrated up to 150 mg/d) or placebo (n =24) in a total 12-week double-blind trial. The primary outcome measure was the Cambridge Neuropsychological Test Automated Battery (CANTAB), assessing visual memory, working memory, attention, and executive function. The secondary outcome measures were the Positive and Negative Syndrome Scale, the Scale for the Assessment of Negative Symptoms, the Quality of Life Scale, and the Montgomery-Åsberg Depression Rating Scale. Fluvoxamine was well tolerated. No significant time × group interaction effects were observed in the scores of the CANTAB, Positive and Negative Syndrome Scale, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, or the Montgomery-Åsberg Depression Rating Scale. However, in secondary analyses, the change from baseline to end point on the Spatial Working Memory strategy score (executive function) of CANTAB improved in the fluvoxamine group. This study suggests no major benefit of fluvoxamine adjunctive therapy to improve cognitive impairments in patients with schizophrenia. Nevertheless, a further study using a large sample size will be needed to confirm the secondary analyses findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia

Niitsu

Fujisaki²,

Shiina³

et al. 2012

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…(Ellingrod et al 2002) Poor metabolizers given antipsychotics with limited dose ranges are more prone to adverse effects, while ultrarapid inducers will not respond to normal antipsychotic doses. Several research studies have looked into the significance of CYP2D6 genetic polymorphism in developing side effects, particularly EPS, following antipsychotic medication (Takashi et al 2002). PMs on risperidone have a three-fold higher chance of having harmful effects than EM or IM patients.…”

Section: Cyp2d6mentioning

confidence: 99%

Olanzapine Use in Schizophrenia and the Modulation of Its Response by Genetic Variations

2022

View full text Add to dashboard Cite

Schizophrenia is a chronic disease with diverse psychopathology and multiple phases of illness. Consequently, numerous factors must be considered when assessing the benefits of a given treatment over short- and long-term periods. Olanzapine is an atypical antipsychotic reported to be effective without producing many of the disabling extrapyramidal adverse effects associated with older, typical antipsychotic drugs. Despite the fact that olanzapine is still associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. This review focuses on the epidemiology, pathogenesis, and treatment of schizophrenia with special emphasis on the role of olanzapine in the treatment of schizophrenia. Genetic variants associated with the therapeutic efficacy and adverse effects of olanzapine are reviewed and those with the potential to act as a clinical predictor of therapeutic response and/or adverse effects are discussed. Recommendations are made for the use of some of these genetic variants in clinical medicine.

show abstract

Current Awareness

2002

Human Psychopharmacology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs ‐ General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Fluvoxamine augmentation in risperidone‐resistant schizophrenia: an open trial

Cited by 13 publications

References 27 publications

A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia

Olanzapine Use in Schizophrenia and the Modulation of Its Response by Genetic Variations

Current Awareness

Contact Info

Product

Resources

About